Table 2.

Summary of recommendations for viral replication targeted antivirals. A list of all of the antivirals discussed in the viral replication section is provided, as well as an indication of when in the progression of the disease they are recommended. Note that no antivirals are recommended as preventative treatment (before one is infected); the majority are recommended for mild to moderate infection, only one is recommended for individuals who might develop severe infection, and three are not currently authorized for COVID‐19 treatment.

Antiviral	Timing of treatment	References
Paxlovid	Mild to moderate infection	[76, 77]
Kaletra	Not authorized for COVID‐19 treatment	[78]
Remdesivir	Infection with high risk to develop severe infection	[79]
Ribavirin	Not authorized for COVID‐19 treatment	[48, 49]
Favipiravir	Not authorized for COVID‐19 treatment	[80]
Molnupiravir	Mild to moderate infection	[81]